Turmeric Drug Interactions
Turmeric in food is not a drug interaction problem. The seasoning in a curry delivers a small amount of poorly absorbed curcumin, and the interaction literature is not about that. It is about the supplement — the concentrated extract, usually with an absorption enhancer, taken daily — which can plausibly change how much of a medicine reaches your blood.
The other thing to say up front is that most of what circulates about turmeric interactions is weaker than it sounds. Interaction lists get assembled from laboratory experiments and then repeated until they acquire the tone of established fact. This page is organised by how good the evidence is, strongest first, and every item is labelled with what kind of study it came from. The single best human finding is not the one most people have heard of.
Table of Contents
- How to Read This Page
- Sulfasalazine and the BCRP Transporter
- What Else the BCRP Pump Moves
- Tacrolimus, Cyclosporine and Transplant Medicine
- Blood Thinners and Antiplatelet Drugs
- Liver Enzymes (CYP) — What Is Actually Known
- Iron
- Black Pepper Is Part of the Dose
- Interactions That Are Plausible but Unproven
- Practical Rules
- Key Research Papers
- Connections
- Featured Videos
How to Read This Page
Interaction claims come in tiers, and confusing the tiers is how misinformation gets made. In descending order of how much a claim should move your behaviour:
- Human pharmacokinetic study. People took the drug with and without curcumin, and blood levels were measured. This is the gold standard for an interaction question, and the sulfasalazine study below is the one example of it in this article.
- Human case report or case series. Something happened to a real patient and a clinician wrote it up carefully. It cannot tell you how often, and it can be confounded, but it is a person rather than a cell.
- Animal study. Informative about mechanism, unreliable about magnitude. Mice and rats handle curcumin differently from humans, and dose scaling across species is notoriously slippery.
- In-vitro study. Cells, enzymes or tissue in a dish. Essential for working out mechanism, and almost useless for predicting what happens in a person — the concentrations used are usually far above anything achievable in human blood, and nothing in a dish has a gut wall, a liver blood supply or kidneys.
Curcumin has a specific extra problem at tier 4 that is worth knowing about. In a widely discussed 2017 analysis in the Journal of Medicinal Chemistry, Nelson and colleagues argued that curcumin behaves as a pan-assay interference compound — a molecule with chemical properties that make it produce apparent "hits" in a great many laboratory assays through mechanisms that have nothing to do with a real biological effect. That critique does not touch well-conducted human trials. It does mean that a laboratory finding about curcumin deserves more scepticism than a laboratory finding about an ordinary drug, and it is one reason this page refuses to promote in-vitro results into clinical warnings.
Sulfasalazine and the BCRP Transporter
Evidence tier: human pharmacokinetic study. This is the strongest interaction finding on the page.
In 2012, Kusuhara, Furuie, Inano and colleagues published a study in the British Journal of Pharmacology examining sulfasalazine pharmacokinetics in healthy volunteers and testing curcumin as an in-vivo inhibitor of BCRP. Curcumin raised sulfasalazine exposure.
The mechanism is a transporter rather than an enzyme, which makes it easier to picture. BCRP — breast cancer resistance protein, also called ABCG2 — is an efflux pump. It sits in the membrane of cells lining the gut and grabs certain molecules as they try to cross into the bloodstream, pushing them straight back into the intestine. Think of it as a bouncer on the inside of the gut wall. Sulfasalazine is one of its regular customers, which is why so little of an oral dose normally gets absorbed — and, incidentally, why sulfasalazine works where it does: the drug is supposed to stay in the colon, where it is split by gut bacteria into its active pieces.
Curcumin inhibits that bouncer. With BCRP working less hard, more sulfasalazine slips through into the blood. The supporting mechanistic work comes from Shukla, Zaher, Hartz and colleagues, whose 2009 study in Pharmaceutical Research showed curcumin inhibiting ABCG2/BCRP1 activity in mice and in cell systems — animal and in-vitro work that explains the human observation rather than standing in for it.
What it means in practice. Higher systemic exposure to sulfasalazine is not automatically dangerous — it is not a drug with a knife-edge therapeutic window — but it is a real change, and it can cut both ways. More drug in the blood means a greater chance of the systemic side effects (nausea, headache, rash, and the blood-count and liver-enzyme changes the drug is monitored for). And because absorbed drug is drug that did not reach the colon, a large enough shift could in principle reduce the local effect that treatment depends on in ulcerative colitis. Neither of those has been demonstrated as a clinical outcome; the measured finding is the exposure change.
If you take sulfasalazine for inflammatory bowel disease or rheumatoid arthritis, this is the one item on this page worth raising with your prescriber before starting a curcumin supplement — a conversation that is easy to have, especially since curcumin is often suggested for exactly those conditions.
What Else the BCRP Pump Moves
BCRP is not a sulfasalazine-specific transporter. It handles a range of substances, which raises a reasonable question: if curcumin inhibits the pump, does it raise exposure to everything the pump moves?
The honest answer is that it might, and that this has not been tested. Sulfasalazine was chosen for the human study partly because it is such a clean BCRP probe — its absorption is dominated by that one transporter, so a change in the transporter shows up loudly. For most other BCRP substrates, absorption depends on several processes at once, and blocking one of them may or may not produce a measurable change. Extrapolating from one probe drug to a whole class is exactly the kind of leap that fills interaction databases with entries nobody has verified.
So what follows is not a warning list. It is the reason to mention a turmeric supplement when a pharmacist asks what else you take, particularly if you are on a medicine with a narrow margin or one whose blood level is monitored. Transporter-mediated interactions are a genuinely active area of pharmacology, and they are less familiar to most people than the liver-enzyme story that usually dominates the conversation.
One practical corollary worth knowing: interactions at the gut wall depend on the two things being in the gut together. Separating a supplement from a medicine by several hours reduces — though it does not eliminate — that kind of interaction, in a way that has no equivalent for interactions that work by changing liver enzyme levels over days.
Tacrolimus, Cyclosporine and Transplant Medicine
Evidence tier: three human case reports. Low on the hierarchy, high on the consequences.
Tacrolimus and cyclosporine are calcineurin inhibitors — the drugs that stop a transplanted organ being rejected. They have narrow therapeutic windows, which is why transplant patients have their blood levels measured repeatedly, sometimes for life. Too little and the graft is at risk. Too much and the drug damages the kidneys, among other things. The gap between those two states is small enough that transplant teams adjust doses in fine increments and worry about grapefruit juice.
Three published case reports involve turmeric:
- Boissiere and colleagues (2023), in the European Journal of Hospital Pharmacy, reported spice–drug interactions in a renal transplant patient on tacrolimus who was using turmeric, curry and ginger. Notably, this is a report about culinary spice use in a patient population where the margin for error is unusually thin — a reminder that "it is only food" is a weaker argument in transplant medicine than anywhere else.
- Nayeri and colleagues (2017), in Transplantation Proceedings, described acute calcineurin-inhibitor nephrotoxicity secondary to turmeric intake — kidney injury from the immunosuppressant itself, attributed to turmeric raising its level.
- A 2010 Swedish report in Läkartidningen, published without a listed author, described a possible interaction between turmeric and tacrolimus.
The plausible mechanism is that curcumin and piperine interfere with the enzymes and transporters that clear tacrolimus — principally CYP3A4 and P-glycoprotein — so that the same prescribed dose produces a higher blood level. That is the same mechanism by which grapefruit juice raises tacrolimus, which transplant teams already warn about routinely.
Three case reports would ordinarily be a weak basis for a recommendation. Here they are enough, for a straightforward reason: the cost of avoiding turmeric supplements is close to zero, and the cost of being wrong is graft loss or kidney injury. That asymmetry, not the strength of the evidence, is what makes this a firm line. If you have a transplant, treat turmeric supplements as a medicine that needs clearing with your transplant team, and tell them about culinary changes too if your spice intake shifts substantially. The same reasoning applies to other narrow-therapeutic-index drugs — lithium, digoxin, some antiepileptics — where nobody has studied curcumin but where the consequences of an unmeasured shift are similarly poor.
Blood Thinners and Antiplatelet Drugs
Evidence tier: a human observational interaction study that found nothing, plus a theoretical mechanism. Report this one carefully.
This is the interaction people have most often heard about and the one where the popular account has drifted furthest from the data.
The theory. Curcumin has been shown in laboratory work to interfere with platelet aggregation — the clumping step that starts a clot. If a supplement makes platelets less sticky, and you are already taking a drug designed to make platelets less sticky (aspirin, clopidogrel) or to slow clotting (warfarin, apixaban, rivaroxaban), then in principle the two effects add up and bleeding risk rises. That reasoning is sound as far as it goes, and it is why turmeric appears on nearly every "herbs that thin the blood" list.
The study. In 2018, Hu, Belcaro, Dugall and colleagues published an interaction study in the European Review for Medical and Pharmacological Sciences looking at a bioavailable curcumin formulation (Meriva) alongside antiplatelet agents, anticoagulants and thyroid replacement therapy in people actually taking those drugs. It reported no significant interaction.
That is the finding, and it should be reported as such rather than buried because it is inconvenient for a tidy warning. It has limits — it is an observational registry-style study rather than a randomised trial, it examined one specific bioavailable formulation, and a study that finds nothing can always be underpowered to detect a small effect. But it is human data in the relevant population, and it is the only human data here. It does not support the confident claim that curcumin meaningfully potentiates anticoagulants.
So what should you do? Two different situations, two different answers.
- Day to day, on a stable anticoagulant: the evidence does not show a problem. If you are on warfarin, you already have a monitoring system — INR checks — that will detect a real change. Starting a curcumin supplement is a reasonable thing to mention to whoever manages your INR, and then to watch in the ordinary way. Do not start and stop it erratically; consistency is what keeps INR stable, and irregular use of anything that might nudge it is worse than steady use.
- Around surgery or a procedure: stop it. Not because harm is proven, but because the calculation is lopsided. Surgeons routinely ask patients to pause supplements a week or two before an operation, and the cost of doing so is nothing at all. This is prudence, not evidence of danger, and it is worth saying which of the two it is.
If you notice easy bruising, bleeding gums, nosebleeds or blood in urine or stool after starting any supplement while on a blood thinner, that is worth reporting regardless of what the studies say. Individual responses exist even where average effects do not.
Liver Enzymes (CYP) — What Is Actually Known
The cytochrome P450 enzymes are the liver's main chemical-processing system, and they metabolise a large share of prescription drugs. CYP3A4 alone handles a substantial fraction of the pharmacopoeia. Anything that inhibits or induces these enzymes can shift drug levels, which is why the CYP system is the first place pharmacologists look for an interaction — and why "curcumin inhibits CYP enzymes" is such a widely repeated claim.
Here is the state of the evidence, stated plainly.
What exists: a large body of laboratory work, in cells and in liver preparations, showing that curcumin can inhibit various CYP enzymes at the concentrations used in those experiments.
What is missing: human studies showing that taking a curcumin supplement meaningfully changes the blood level of a CYP-metabolised drug in a person. Given how badly absorbed curcumin is, the concentrations that reach a human liver are typically far below those used in the dish.
One study in this area is frequently cited in a way that overstates it, so it is worth naming precisely. Burkina, Zamaratskaia and Rasmussen published work in Xenobiotica in 2022 on how curcumin and quercetin modify warfarin-induced regulation of CYP1A2 and CYP3A expression and activity. That study was done in porcine cells — pig liver cells in a dish. It is a laboratory experiment about enzyme regulation in a non-human cell system. It is not a study of warfarin in people, it did not measure anybody's INR, and it cannot tell you what happens if you take curcumin while on warfarin. It is cited here because it is real work that belongs in the mechanistic picture, and because it is exactly the kind of paper that gets summarised online as "study shows curcumin interacts with warfarin." It shows nothing of the kind.
The practical upshot: treat "curcumin inhibits CYP3A4 in humans at supplement doses" as an open question rather than an established fact. The genuine reason for caution in this area is not curcumin itself — it is the piperine sitting next to it in the capsule, which is covered below and which has human pharmacokinetic evidence behind it.
Iron
Evidence tier: animal and in-vitro mechanism, plus one human case report.
Curcumin binds iron. Jiao, Wilkinson, Di and colleagues demonstrated in Blood in 2009 that curcumin is a biologically active iron chelator — not merely that it sticks to iron in a test tube, but that in animals it produced the downstream signs of iron depletion, affecting the proteins that regulate iron handling.
The clinical counterpart is a single case: Smith and Ashar reported in Cureus in 2019 on iron-deficiency anaemia attributed to high-dose turmeric, in which the anaemia resolved after the turmeric was stopped. One case report is one case report. But it is coherent with a well-characterised mechanism, and the resolution on withdrawal is the kind of detail that makes an attribution more convincing.
Who this matters to:
- Anyone already iron-deficient, or with low-normal ferritin. If you are being treated for iron deficiency and taking a high-dose curcumin supplement, you have two things pulling in opposite directions, and the supplement is the easier one to remove.
- People with heavy menstrual bleeding, on plant-based diets, with coeliac disease or other malabsorption, or who have had bariatric surgery — the groups whose iron stores already sit close to the line.
- Anyone taking an iron supplement. Separate the two by several hours at minimum. Binding happens in the gut, so timing genuinely helps.
Two things this does not mean. It is not a reason to avoid turmeric in cooking — the culinary amounts involved are not what produced the case report, and plenty of iron-rich cuisines are built on turmeric. And for people who are not iron-deficient, mild iron chelation is not obviously harmful; some of curcumin's proposed effects have been attributed to exactly this property. The problem is specific to people whose iron is already low.
Black Pepper Is Part of the Dose
Most people think of black pepper extract in a curcumin capsule as a clever trick for getting more out of the turmeric. It is that. It is also, in its own right, the most under-discussed interaction risk in the product.
The foundational study is Shoba, Joy, Joseph and colleagues in Planta Medica in 1998, which measured curcumin pharmacokinetics in animals and in human volunteers with and without piperine, the active alkaloid of black pepper. The increase in curcumin bioavailability with a small dose of piperine was very large.
Now look at the mechanism from the other direction. Piperine does not have a switch that reads "enhance curcumin only." It works by inhibiting the drug-metabolising machinery — the glucuronidation enzymes that dispose of absorbed curcumin, with additional effects on oxidative metabolism and on intestinal efflux. Those are the same systems that clear a great many prescription medicines. A compound that raises the blood level of one poorly absorbed molecule by blocking its disposal is, by construction, capable of raising the blood level of others.
Two consequences follow, and they are the practical heart of this page.
- "Turmeric with black pepper" is the higher-interaction form of the supplement. If you take several prescription medicines and want to try curcumin anyway, a formulation that achieves absorption by a physical route — a lipid or phospholipid carrier, a micelle, a submicron particle — rather than by inhibiting your metabolism is the more conservative choice. Our bioavailability and forms page sets out which is which.
- The enhancer is also part of the liver-injury picture. Enhanced products deliver far more curcumin to the liver at the same label dose, which is one reason the case literature is dominated by supplements rather than by the spice.
None of this applies to pepper on your dinner. The doses of piperine used as supplement enhancers are standardised extracts, not a twist of the grinder.
Interactions That Are Plausible but Unproven
Several turmeric interaction claims are repeated widely without human evidence behind them. They are listed here so you can recognise them, not so you can worry about them. Each is a reasonable hypothesis and none has been demonstrated in people at supplement doses.
- Diabetes medicines. Curcumin has been studied for effects on blood glucose, so the suggestion that it might add to a glucose-lowering drug is coherent. If you take insulin or a sulfonylurea and start any new supplement, a fortnight of slightly more attentive glucose monitoring is a sensible, low-effort response — the same thing you would do after any change in diet.
- Blood-pressure medicines. Same logic, same modest response.
- Stomach-acid medicines. Turmeric affects gut motility and secretion in various ways; whether that changes the absorption of co-administered drugs in practice has not been shown.
- Chemotherapy. This one deserves a firmer line, not because an interaction is proven but because the stakes are high, many chemotherapy agents are BCRP or CYP substrates, and antioxidant supplementation during treatment is a genuinely contested question among oncologists. Anyone in active cancer treatment should clear supplements with their oncology team rather than reason it out from a website — this one included.
- Thyroid replacement. The Meriva interaction study discussed above included thyroid replacement therapy among the medicines examined and did not report a significant interaction.
For any of these, searching the primary literature yourself is easy, and the topic-search links at the end of this page are a starting point.
Practical Rules
- Put the supplement on your medication list. Not "I take some turmeric" — the actual product, the dose, the formulation and whether it contains black pepper extract. Pharmacists are good at this question and it costs nothing to ask.
- Separate it from your medicines by a few hours where you reasonably can. Transporter and chelation interactions happen in the gut, and not being in the gut at the same time genuinely reduces them.
- Be consistent. For anything that is monitored by blood level — INR, tacrolimus trough, thyroid function — a steady daily habit is far safer than starting and stopping, because monitoring detects a stable shift and is defeated by a moving target.
- Stop before surgery. A week or two, no debate needed.
- Prefer single-ingredient, clearly labelled products. A capsule with six botanicals in it has six interaction profiles and no way to work out which one caused a problem.
- Treat transplant medicine, chemotherapy and narrow-therapeutic-index drugs as a different category entirely. There, the right move is to ask the team, not to weigh the evidence yourself.
Key Research Papers
- Kusuhara H, Furuie H, Inano A, et al. (2012). Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol. — PubMed PMID: 22300367 (human pharmacokinetic study — the strongest interaction evidence on this page)
- Shukla S, Zaher H, Hartz A, et al. (2009). Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. — PubMed PMID: 18841445 (animal and in-vitro mechanism)
- Boissiere C, Francois E, Vabret E, et al. (2023). Spice-drug interactions: a case report on the use of turmeric, curry and ginger in a renal transplant patient on tacrolimus. Eur J Hosp Pharm. — PubMed PMID: 37586787 (case report)
- Nayeri A, Wu S, Adams E, et al. (2017). Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report. Transplant Proc. — PubMed PMID: 28104136 (case report)
- (2010). [Interaction between turmeric and tacrolimus possible]. Lakartidningen. — PubMed PMID: 20521597 (case report; no author list is returned for this record)
- Hu S, Belcaro G, Dugall M, et al. (2018). Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva). Eur Rev Med Pharmacol Sci. — PubMed PMID: 30070343 (human study; reported no significant interaction)
- Burkina V, Zamaratskaia G, Rasmussen MK. (2022). Curcumin and quercetin modify warfarin-induced regulation of porcine CYP1A2 and CYP3A expression and activity in vitro. Xenobiotica. — PubMed PMID: 35695287 (in vitro, porcine cells — not evidence about warfarin in people)
- Jiao Y, Wilkinson J 4th, Di X, et al. (2009). Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. — PubMed PMID: 18815282 (animal and in-vitro)
- Smith TJ, Ashar BH. (2019). Iron Deficiency Anemia Due to High-dose Turmeric. Cureus. — PubMed PMID: 30899609 (case report)
- Shoba G, Joy D, Joseph T, et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. — PubMed PMID: 9619120
- Nelson KM, Dahlin JL, Bisson J, et al. (2017). The Essential Medicinal Chemistry of Curcumin. J Med Chem. — PubMed PMID: 28074653 (why laboratory findings about curcumin need extra scepticism)
- Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. (2023). Liver Injury Associated with Turmeric—A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. — PubMed PMID: 36252717